Skip to content
Sign in
StableHealthReported 2026-11-19 13:19

Novo Nordisk research shows that semaglutide can significantly reduce BMI in obese children.

The Phase 3 STEP Young trial by Novo Nordisk found that after 68 weeks of semaglutide treatment, the average BMI of obese children decreased by 13.5%, with 40% of children no longer classified as obese.

Why it matters. This study provides new drug options for the treatment of childhood obesity, which may influence related medical practices and policies.

01

Evidence

  • CcnBetaMedia2026-11-19 13:19
    View source